Host-Pathogen Relationship in Skin and Soft Tissue Infections Caused by Group A streptococcus and Staphylococcus aureus

Bacterial Virulence: Basic Principles, Models and Global Approaches

Volumn , Issue , 2010, Pages 43-68

  Mishalian, Inbal ^a   Ravins, Miriam ^a   Baruch, Moshe ^a   Persky, Merav ^a   Belotserkovsky, Ilia ^a   Hanski, Emanuel ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Bacterial resistance mechanisms; Cationic antimicrobial peptides; Group A streptococcus (GAS); Host pathogen relationship; Leukocytes; Skin infection; Soft tissue infections; Staphylococcus aureus (SA)

Indexed keywords

EID: 82755178723     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527629664.ch4     Document Type: Chapter

References (168)

1. Carapetis, J.R., et al. (2005) The global burden of group a streptococcal diseases. Lancet Infect. Dis., 5 (11), 685-694.
2. O'Loughlin, R.E., et al. (2007) The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin. Infect. Dis., 45 (7), 853-862.
3. McCaig, L.F., et al. (2006) Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care. Emerg. Infect. Dis., 12 (11), 1715-1723.
4. Elston, D.M. (2007) Community-acquired methicillin-resistant Staphylococcus aureus. J. Am. Acad. Dermatol., 56 (1), 1-16, quiz 1720.
5. Lowy, F.D. (1998) Staphylococcus aureus infections. N. Engl.J. Med., 339 (8), 520-532.
6. Vinh, D.C., and Embil, J.M. (2005) Rapidly progressive soft tissue infections. Lancet Infect. Dis., 5 (8), 501-513.
7. Vandenesch, F., et al. (2003) Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg. Infect. Dis., 9 (8), 978-984.
8. Klevens, R.M., et al. (2007) Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA, 298 (15), 1763-1771.
9. Chavakis, T., Preissner, K.T., and Herrmann, M. (2007) The antiinflammatory activities of Staphylococcus aureus. Trends Immunol., 28 (9), 408-418.
10. Fournier, B., and Philpott, D.J. (2005) Recognition of Staphylococcus aureus by the innate immune system. Clin. Microbiol. Rev., 18 (3), 521-540.
11. Iwatsuki, K., et al. (2006) Staphylococcal cutaneous infections: invasion, evasion and aggression. J. Dermatol. Sci., 42 (3), 203-214.
12. Kwinn, L.A., and Nizet, V. (2007) How group A Streptococcus circumvents host phagocyte defenses. Future Microbiol., 75-84.2
13. Nizet, V. (2007) Understanding how leading bacterial pathogens subvert innate immunity to reveal novel therapeutic targets. J. Allergy Clin. Immunol., 120 (1), 13-22.
14. Rooijakkers, S.H., van Kessel, K.P., and van Strijp, J.A. (2005) Staphylococcal innate immune evasion. Trends Microbiol., 13 (12), 596-601.
15. Voyich, J.M., Musser, J.M., and DeLeo, F.R. (2004) Streptococcus pyogenes and human neutrophils: a paradigm for evasion of innate host defense by bacterial pathogens. Microbes Infect., 6 (12), 1117-1123.
16. Beutler, B. (2004) Innate immunity: an overview. Mol. Immunol., 40 (12), 845-859.
17. Ishii, K.J., et al. (2008) Host innate immune receptors and beyond: making sense of microbial infections. Cell Host Microbe, 3 (6), 352-363.
18. Medzhitov, R. (2007) Recognition of microorganisms and activation of the immune response. Nature, 449 (7164), 819-826.
19. Goodarzi, H., Trowbridge, J., and Gallo, R.L. (2007) Innate immunity: a cutaneous perspective. Clin. Rev. Allergy Immunol., 33(1-2), 15-26.
20. Aderem, A., and Underhill, D.M. (1999) Mechanisms of phagocytosis in macrophages. Annu. Rev. Immunol., 17, 593-623.
21. Stuart, L.M., and Ezekowitz, R.A. (2005) Phagocytosis: elegant complexity. Immunity, 22 (5), 539-550.
22. Gordon, S., and Taylor, P.R. (2005) Monocyte and macrophage heterogeneity. Nat. Rev. Immunol., 5 (12), 953-964.
23. Imhof, B.A., and Aurrand-Lions, M. (2004) Adhesion mechanisms regulating the migration of monocytes. Nat. Rev. Immunol., 4 (6), 432-444.
24. Ley, K., et al. (2007) Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol., 7 (9), 678-689.
25. Rot, A., and von Andrian, U.H. (2004) Chemokines in innate and adaptive host defense: basic chemokinase grammar for immune cells. Annu. Rev. Immunol., 891-928.22
26. Nathan, C. (2006) Neutrophils and immunity: challenges and opportunities. Nat. Rev. Immunol., 6 (3), 173-182.
27. Segal, A.W. (2005) How neutrophils kill microbes. Annu. Rev. Immunol., 23, 197-223.
28. Gordon, S. (2007) The macrophage: past, present and future. Eur. J. Immunol., 37 (Suppl. 1), S9-S17.
29. Soehnlein, O., et al. (2008) Neutrophil secretion products pave the way for inflammatory monocytes. Blood, 112 (4), 1461-1471.
30. Gallo, R.L., and Huttner, K.M. (1998) Antimicrobial peptides: an emerging concept in cutaneous biology. J. Invest. Dermatol., 111 (5), 739-743.
31. Niyonsaba, F., and Ogawa, H. (2005) Protective roles of the skin against infection: implication of naturally occurring human antimicrobial agents beta-defensins, cathelicidin LL-37 and lysozyme. J. Dermatol. Sci., 40 (3), 157-168.
32. Yamasaki, K., and Gallo, R.L. (2008) Antimicrobial peptides in human skin disease. Eur. J. Dermatol., 18 (1), 11-21.
33. Hancock, R.E., and Chapple, D.S. (1999) Peptide antibiotics. Antimicrob. Agents Chemother., 43 (6), 1317-1323.
34. Lehrer, R.I., and Ganz, T. (1999) Antimicrobial peptides in mammalian and insect host defence. Curr. Opin. Immunol., 11 (1), 23-27.
35. Hale, J.D., and Hancock, R.E. (2007) Alternative mechanisms of action of cationic antimicrobial peptides on bacteria. Expert Rev. Anti. Infect. Ther., 5 (6), 951-959.
36. Dorschner, R.A., et al. (2001) Cutaneous injury induces the release of cathelicidin anti-microbial peptides active against group A Streptococcus. J. Invest. Dermatol., 117 (1), 91-97.
37. Nizet, V., et al. (2001) Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature, 414 (6862), 454-457.
38. Kisich, K.O., et al. (2007) The constitutive capacity of human keratinocytes to kill Staphylococcus aureus is dependent on beta-defensin 3. J. Invest. Dermatol., 127 (10), 2368-2380.
39. Kisich, K.O., et al. (2008) Defective killing of Staphylococcus aureus in atopic dermatitis is associated with reduced mobilization of human beta-defensin-3. J. Allergy Clin. Immunol., 122 (1), 62-68.
40. Peschel, A. (2002) How do bacteria resist human antimicrobial peptides? Trends Microbiol., 10 (4), 179-186.
41. Peschel, A., and Sahl, H.G. (2006) The co-evolution of host cationic antimicrobial peptides and microbial resistance. Nat. Rev. Microbiol., 4 (7), 529-536.
42. Collins, L.V., et al. (2002) Staphylococcus aureus strains lacking D-alanine modifications of teichoic acids are highly susceptible to human neutrophil killing and are virulence attenuated in mice. J. Infect. Dis., 186 (2), 214-219.
43. Kristian, S.A., et al. (2005) D-alanyla-tion of teichoic acids promotes group a streptococcus antimicrobial peptide resistance, neutrophil survival, and epithelial cell invasion. J. Bacteriol., 187 (19), 6719-6725.
44. Kristian, S.A., et al. (2003) Alanylation of teichoic acids protects Staphylococcus aureus against Toll-like receptor 2-dependent host defense in a mouse tissue cage infection model. J. Infect. Dis., 188 (3), 414-423.
45. Peschel, A., et al. (2001) Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with L-lysine. J. Exp. Med., 193 (9), 1067-1076.
46. Peschel, A., et al. (1999) Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J. Biol. Chem., 274 (13), 8405-8410.
47. Sieprawska-Lupa, M., et al. (2004) Degradation of human antimicrobial peptide LL-37 by Staphylococcus aureus-derived proteinases. Antimicrob. Agents Chemother., 48 (12), 4673-4679.
48. Nyberg, P., Rasmussen, M., and Bjorck, L. (2004) alpha2-Macroglobulin-proteinase complexes protect Streptococcus pyogenes from killing by the antimicrobial peptide LL-37. J. Biol. Chem, 279 (51), 52820-52823.
49. Frick, I.M., et al. (2003) SIC, a secreted protein of Streptococcus pyogenes that inactivates antibacterial peptides. J.Biol. Chem., 278 (19), 16561-16566.
50. Jin, T., et al. (2004) Staphylococcus aureus resists human defensins by production of staphylokinase, a novel bacterial evasion mechanism. J. Immunol., 172 (2), 1169-1176.
51. Clarke, S.R., et al. (2007) The Staphylococcus aureus surface protein IsdA mediates resistance to innate defenses of human skin. Cell Host Microbe, 1 (3), 199-212.
52. Molne, L., Verdrengh, M., and Tarkowski, A. (2000) Role of neutrophil leukocytes in cutaneous infection caused by Staphylococcus aureus. Infect. Immun., 68 (11), 6162-6167.
53. Gonzalez-Barca, E., et al. (2001) Predisposing factors and outcome of Staphylococcus aureus bacteremia in neutropenic patients with cancer. Eur. J. Clin. Microbiol. Infect. Dis., 20 (2), 117-119.
54. Vallalta Morales, M., et al. (2006) Group A streptococcal bacteremia: outcome and prognostic factors. Rev. Esp. Quimioter., 19 (4), 367-375.
55. Agarwal, D.S. (1967) Subcutaneous staphylococcal infection in mice. II. The inflammatory response to different strains of staphylococci and micrococci. Br. J. Exp. Pathol., 48 (5), 468-482.
56. Hill, M.J. (1968) A staphylococcal aggressin. J. Med. Microbiol., 1 (1), 31-43.
57. Russell, R.J., et al. (1976) Effects of staphylococcal products on locomotion and chemotaxis of human blood neutrophils and monocytes. J. Med. Microbiol., 9 (4), 433-439.
58. Cockerill, F.R., 3rd, et al. (1998) Molecular, serological, and clinical features of 16 consecutive cases of invasive streptococcal disease. Southeastern Minnesota Streptococcal Working Group. Clin. Infect. Dis., 26 (6), 1448-1458
59. Norrby-Teglund, A., et al. (2001) Evidence for superantigen involvement in severe group A streptococcal tissue infections. J. Infect. Dis., 184 (7), 853-860.
60. Taylor, F.B., Jr., et al. (1999) Staging of the baboon response to group A streptococci administered intramuscularly: a descriptive study of the clinical symptoms and clinical chemical response patterns. Clin. Infect. Dis., 29 (1), 167-177.
61. Hidalgo-Grass, C., et al. (2004) Effect of a bacterial pheromone peptide on host chemokine degradation in group A streptococcal necrotising soft-tissue infections. Lancet, 363 (9410), 696-703.
62. Bakleh, M., et al. (2005) Correlation of histopathologic findings with clinical outcome in necrotizing fasciitis. Clin. Infect. Dis., 40 (3), 410-414.
63. Akira, S., and Takeda, K. (2004) Toll-like receptor signalling. Nat. Rev. Immunol., 4 (7), 499-511.
64. Hoebe, K., et al. (2005) CD36 is a sensor of diacylglycerides. Nature, 433 (7025), 523-527.
65. Takeuchi, O., et al. (2000) Cutting edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a toll-like receptor 2- and MyD88-dependent signaling pathway. J. Immunol., 164 (2), 554-557.
66. Miller, L.S., et al. (2006) MyD88 mediates neutrophil recruitment initiated by IL-1R but not TLR2 activation in immunity against Staphylococcus aureus. Immunity, 24 (1), 79-91.
67. Miller, L.S., et al. (2007) Inflammas-ome-mediated production of IL-1beta is required for neutrophil recruitment against Staphylococcus aureus in vivo. J. Immunol., 179 (10), 6933-6942.
68. von Bernuth, H., et al. (2008) Pyogenic bacterial infections in humans with MyD88 deficiency. Science, 321 (5889), 691-696.
69. Loof, T.G., et al. (2007) The contribution of dendritic cells to host defenses against Streptococcus pyogenes. J. Infect. Dis., 196 (12), 1794-1803.
70. Loof, T.G., Goldmann, O., and Medina, E. (2008) Immune recognition of Streptococcus pyogenes by dendritic cells. Infect. Immun., 76 (6), 2785-2792.
71. Gratz, N., et al. (2008) Group A streptococcus activates type I interferon production and MyD88-dependent signaling without involvement of TLR2, TLR4, and TLR9. J. Biol. Chem., 283 (29), 19879-19887.
72. Gomez, M.I., et al. (2004) Staphylococcus aureus protein A induces airway epithelial inflammatory responses by activating TNFR1. Nat. Med., 10 (8), 842-848.
73. Gomez, M.I., et al. (2006) Staphylococcus aureus protein A activates TNFR1 signaling through conserved IgG binding domains. J. Biol. Chem., 281 (29), 20190-20196.
74. Gomez, M.I., Seaghdha, M.O., and Prince, A.S. (2007) Staphylococcus aureus protein A activates TACE through EGFR-dependent signaling. EMBO J., 26 (3), 701-709.
75. Herwald, H., et al. (2004) M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. Cell, 116 (3), 367-379.
76. Pahlman, L.I., et al. (2006) Streptococcal M protein: a multipotent and powerful inducer of inflammation. J. Immunol., 177 (2), 1221-1228.
77. Jarva, H., et al. (2003) Complement resistance mechanisms of streptococci. Mol. Immunol., 40 (2-4), 95-107.
78. Kraiczy, P., and Wurzner, R. (2006) Complement escape of human pathogenic bacteria by acquisition of complement regulators. Mol. Immunol., 43 (1-2), 31-44.
79. Lindahl, G., Sjobring, U., and Johnsson, E. (2000) Human complement regulators: a major target for pathogenic microorganisms. Curr.Opin. Immunol., 12 (1), 44-51.
80. Rooijakkers, S.H., and van Strijp, J.A. (2007) Bacterial complement evasion. Mol. Immunol., 44 (1-3), 23.
81. Springer, T.A. (1995) Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration. Annu. Rev. Physiol., 57, 827-872.
82. Le, Y., Murphy, P.M., and Wang, J.M. (2002) Formyl-peptide receptors revisited. Trends Immunol., 23 (11), 541-548.
83. Guo, R.F., and Ward, P.A. (2005) Role of C5a in inflammatory responses. Annu. Rev. Immunol., 23, 821-852.
84. Chen, C.C., and Cleary, P.P. (1990) Complete nucleotide sequence of the streptococcal C5a peptidase gene of Streptococcus pyogenes. J. Biol. Chem., 265 (6), 3161-3167.
85. Siezen, R.J., et al. (1991) Homology modelling and protein engineering strategy of subtilases, the family of subtilisin-like serine proteinases. Protein Eng., 4 (7), 719-737.
86. Cleary, P.P., et al. (1992) Streptococcal C5a peptidase is a highly specific endopeptidase. Infect. Immun., 60 (12), 5219-5223.
87. Kawai, M., et al. (1991) Identification and synthesis of a receptor binding site of human anaphylatoxin C5a. J. Med. Chem., 34 (7), 2068-2071.
88. Anderson, E.T., et al. (2002) Processing, stability, and kinetic parameters of C5a peptidase from Streptococcus pyogenes. Eur. J. Biochem., 269 (19), 4839-4851.
89. Berge, A., and Bjorck, L. (1995) Streptococcal cysteine proteinase releases biologically active fragments of streptococcal surface proteins. J. Biol. Chem., 270 (17), 9862-9867.
90. Terao, Y., et al. (2006) Multifunctional glyceraldehyde-3-phosphate dehydrogenase of Streptococcus pyogenes is essential for evasion from neutrophils. J. Biol. Chem., 281 (20), 14215-14223.
91. Ji, Y., et al. (1996) C5a peptidase alters clearance and trafficking of group A streptococci by infected mice. Infect. Immun., 64 (2), 503-510.
92. Hidalgo-Grass, C., et al. (2006) A streptococcal protease that degrades CXC chemokines and impairs bacterial clearance from infected tissues. EMBO J., 25 (19), 4628-4637.
93. Bohnsack, J.F., Chang, J.K., and Hill, H.R. (1993) Restricted ability of group B streptococcal C5a-ase to inactivate C5a prepared from different animal species. Infect. Immun., 61 (4), 1421-1426.
94. Edwards, R.J., et al. (2005) Specific C-terminal cleavage and inactivation of interleukin-8 by invasive disease isolates of Streptococcus pyogenes. J. Infect. Dis., 192 (5), 783-790.
95. Sumby, P., et al. (2008) A chemokine-degrading extracellular protease made by group A Streptococcus alters pathogenesis by enhancing evasion of the innate immune response. Infect. Immun., 76 (3), 978-985.
96. Zinkernagel, A.S., et al. (2008) The IL-8 protease SpyCEP/ScpC of group A Streptococcus promotes resistance to neutrophil killing. Cell Host Microbe, 4 (2), 170-178.
97. Gupta, A.K., et al. (2005) Induction of neutrophil extracellular DNA lattices by placental microparticles and IL-8 and their presence in preeclampsia. Hum. Immunol., 66 (11), 1146-1154.
98. Hussain, M., et al. (2002) Insertional inactivation of Eap in Staphylococcus aureus strain Newman confers reduced staphylococcal binding to fibroblasts. Infect. Immun., 70 (6), 2933-2940.
99. Palma, M., Haggar, A., and Flock, J.I. (1999) Adherence of Staphylococcus aureus is enhanced by an endogenous secreted protein with broad binding activity. J. Bacteriol., 181 (9), 2840-2845.
100. Chavakis, T., et al. (2002) Staphylococcus aureus extracellular adherence protein serves as anti-inflammatory factor by inhibiting the recruitment of host leukocytes. Nat. Med., 8 (7), 687-693.
101. Athanasopoulos, A.N., et al. (2006) The extracellular adherence protein (Eap) of Staphylococcus aureus inhibits wound healing by interfering with host defense and repair mechanisms. Blood, 107 (7), 2720-2727.
102. de Haas, C.J., et al. (2004) Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agent. J. Exp. Med., 199 (5), 687-695.
103. Postma, B., et al. (2004) Chemotaxis inhibitory protein of Staphylococcus aureus binds specifically to the C5a and formylated peptide receptor. J. Immunol., 172 (11), 6994-7001.
104. Haas, P.J., et al. (2005) The structure of the C5a receptor-blocking domain of chemotaxis inhibitory protein of Staphylococcus aureus is related to a group of immune evasive molecules. J Mol Biol, 353 (4), 859-872.
105. Wright, A.J., et al. (2007) Characterisation of receptor binding by the chemotaxis inhibitory protein of Staphylococcus aureus and the effects of the host immune response. Mol. Immunol., 44 (10), 2507-2517.
106. Todd, E., and Lancefield, R. (1928) Variants of hemolytic streptococci; their relation to type-specific substance, virulence, and toxin. J. Exp. Med., 48, 751-767.
107. Ward, H., and Lyons, C. (1935) Studies on the hemolytic streptococcus of human origin. I. Observations on the virulent, attenuated, and avirulent variants. J. Exp. Med., 61, 515-529.
108. Ashbaugh, C.D., et al. (1998) Molecular analysis of the role of the group A streptococcal cysteine protease, hyaluronic acid capsule, and M protein in a murine model of human invasive soft-tissue infection. J. Clin. Invest., 102 (3), 550-560.
109. Jacks-Weis, J., Kim, Y., and Cleary, P.P. (1982) Restricted deposition of C3 on M+ group A streptococci: correlation with resistance to phagocytosis. J. Immunol., 128 (4), 1897-1902.
110. Lancefield, R.C. (1962) Current knowledge of type-specific M antigens of group A streptococci. J. Immunol.,89, 307-313.
111. Sutterwala, F.S., Rosenthal, L.A., and Mosser, D.M. (1996) Cooperation between CR1 (CD35) and CR3 (CD 11b/CD18) in the binding of complement-opsonized particles. J. Leukoc. Biol., 59 (6), 883-890.
112. Ehlers, M.R. (2000) CR3: a general purpose adhesion-recognition receptor essential for innate immunity. Microbes Infect., 2 (3), 289-294.
113. DeMaster, E., et al. (2002) M(+) group a streptococci are phagocytized and killed in whole blood by C5a-activated polymorphonuclear leukocytes. Infect. Immun., 70 (1), 350-359.
114. Staali, L., et al. (2003) Streptococcus pyogenes expressing M and M-like surface proteins are phagocytosed but survive inside human neutrophils. Cell Microbiol., 5 (4), 253-265.
115. Staali, L., et al. (2006) Streptococcus pyogenes bacteria modulate membrane traffic in human neutrophils and selectively inhibit azurophilic granule fusion with phagosomes. Cell Microbiol., 8 (4), 690-703.
116. Voyich, J.M., et al. (2003) Genome-wide protective response used by group A Streptococcus to evade destruction by human polymorphonuclear leukocytes. Proc. Natl Acad. Sci. USA, 100 (4), 1996-2001.
117. Voyich, J.M., et al. (2004) Engagement of the pathogen survival response used by group A Streptococcus to avert destruction by innate host defense. J. Immunol., 173 (2), 1194-1201.
118. King, K.Y., Horenstein, J.A., and Caparon, M.G. (2000) Aerotolerance and peroxide resistance in peroxidase and PerR mutants of Streptococcus pyogenes. J. Bacteriol., 182 (19), 5290-5299.
119. Brenot, A., et al. (2004) Contribution of glutathione peroxidase to the virulence of Streptococcus pyogenes. Infect.Immun., 72 (1), 408-413.
120. Nathan, C. (2002) Points of control in inflammation. Nature, 420 (6917), 846-852.
121. Kobayashi, S.D., et al. (2003) Bacterial pathogens modulate an apoptosis differentiation program in human neutrophils. Proc. Natl Acad. Sci. USA, 100 (19), 10948-10953.
122. Brinkmann, V., et al. (2004) Neutrophil extracellular traps kill bacteria. Science, 303 (5663), 1532-1535.
123. Fuchs, T.A., et al. (2007) Novel cell death program leads to neutrophil extracellular traps. J. Cell Biol., 176 (2), 231-241.
124. Urban, C.F., et al. (2006) Neutrophil extracellular traps capture and kill Candida albicans yeast and hyphal forms. Cell Microbiol., 8 (4), 668-676.
125. Sumby, P., et al. (2005) Extracellular deoxyribonuclease made by group A Streptococcus assists pathogenesis by enhancing evasion of the innate immune response. Proc. Natl Acad. Sci. USA, 102 (5), 1679-1684.
126. Buchanan, J.T., et al. (2006) DNase expression allows the pathogen group A Streptococcus to escape killing in neutrophil extracellular traps. Curr. Biol., 16 (4), 396-400.
127. Jongerius, I., et al. (2007) Staphylococcal complement evasion by various convertase-blocking molecules. J. Exp. Med., 204 (10), 2461-2471.
128. Rooijakkers, S.H., et al. (2005) Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat. Immunol., 6 (9), 920-927.
129. Rooijakkers, S.H., et al. (2006) Early expression of SCIN and CHIPS drives instant immune evasion by Staphylococcus aureus. Cell Microbiol., 8 (8), 1282-1293.
130. Van de Velde, H. (1895) Etude sur le mechanisme de la virulence du staphylocoque pyogene. Cellule, 10, 51-54.
131. Kapral, F.A., and Shayegani, M.G. (1959) Intracellular survival of staphylococci. J. Exp. Med., 110 (1), 123-138.
132. Melly, M.A., Thomison, J.B., and Rogers, D.E. (1960) Fate of staphylococci within human leukocytes. J. Exp. Med., 112, 1121-1130.
133. Rogers, D.E., and Melly, M.A. (1960) Further observations on the behavior of staphylococci within human leukocytes. J. Exp. Med., 111, 533-558.
134. Gresham, H.D., et al. (2000) Survival of Staphylococcus aureus inside neutrophils contributes to infection. J. Immunol., 164 (7), 3713-3722.
135. Medina, E., et al. (2003) Survival of Streptococcus pyogenes within host phagocytic cells: a pathogenic mechanism for persistence and systemic invasion. J. Infect. Dis., 187 (4), 597-603.
136. Medina, E., Rohde, M., and Chhatwal, G.S. (2003) Intracellular survival of Streptococcus pyogenes in polymorphonuclear cells results in increased bacterial virulence. Infect. Immun., 71 (9), 5376-5380.
137. Mandell, G.L. (1975) Catalase, superoxide dismutase, and virulence of Staphylococcus aureus. In vitro and in vivo studies with emphasis on staphylococcal-leukocyte interaction. J. Clin. Invest., 55 (3), 561-566.
138. Horsburgh, M.J., Ingham, E., and Foster, S.J. (2001) In Staphylococcus aureus, fur is an interactive regulator with PerR, contributes to virulence, and is necessary for oxidative stress resistance through positive regulation of catalase and iron homeostasis. J. Bacteriol., 183 (2), 468-475.
139. Messina, C.G., et al. (2002) Catalase negative Staphylococcus aureus retain virulence in mouse model of chronic granulomatous disease. FEBS Lett., 518 (1-3), 107-110.
140. Clements, M.O., Watson, S.P., and Foster, S.J. (1999) Characterization of the major superoxide dismutase of Staphylococcus aureus and its role in starvation survival, stress resistance, and pathogenicity. J. Bacteriol., 181 (13), 3898-3903.
141. Karavolos, M.H., et al. (2003) Role and regulation of the superoxide dismutases of Staphylococcus aureus. Microbiology, 149 (Pt 10), 2749-2758.
142. Schneider, W. P., et al. (2002) Virulence gene identification by differential fluorescence induction analysis of Staphylococcus aureus gene expression during infection-simulating culture. Infect. Immun., 70 (3), 1326-1333.
143. Liu, G.Y., et al. (2005) Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity. J. Exp. Med., 202 (2), 209-215.
144. Liu, C. I., et al. (2008) A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science, 319 (5868), 1391-1394.
145. Corbin, B.D., et al. (2008) Metal chelation and inhibition of bacterial growth in tissue abscesses. Science, 319 (5865), 962-965.
146. Yui, S., Nakatani, Y., and Mikami, M. (2003) Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. Biol. Pharm. Bull., 26 (6), 753-760.
147. Li, M., et al. (2007) The antimicrobial peptide-sensing system aps of Staphylococcus aureus. Mol. Microbiol., 66 (5), 1136-1147.
148. Palazzolo-Ballance, A.M., et al. (2008) Neutrophil microbicides induce a pathogen survival response in community-associated methicillin-resistant Staphylococcus aureus. J. Immunol., 180 (1), 500-509.
149. Gillet, Y., et al. (2002) Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet, 359 (9308), 753-759.
150. Labandeira-Rey, M., et al. (2007) Staphylococcus aureus. Panton-Valentine leukocidin causes necrotizing pneumonia. Science, 315 (5815), 1130-1133.
151. Ward, P.D., and Turner, W.H. (1980) Identification of staphylococcal Panton-Valentine leukocidin as a potent dermonecrotic toxin. Infect. Immun., 28 (2), 393-397.
152. Voyich, J.M., et al. (2006) Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J. Infect. Dis., 194 (12), 1761-1770.
153. Bubeck Wardenburg, J., et al. (2007) Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat. Med., 13 (12), 1405-1406.
154. Wang, R., et al. (2007) Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat. Med., 13 (12), 1510-1514.
155. Diep, B.A., and Otto, M. (2008) The role of virulence determinants in community-associated MRSA pathogenesis. Trends Microbiol., 16 (8), 361-369.
156. Underhill, D.M., and Ozinsky, A. (2002) Phagocytosis of microbes: complexity in action. Annu. Rev. Immunol., 20, 825-852.
157. Osterlund, A., and Engstrand, L. (1995) Intracellular penetration and survival of Streptococcus pyogenes in respiratory epithelial cells in vitro. Acta Otolaryngol., 115 (5), 685-688.
158. Thulin, P., et al. (2006) Viable group A streptococci in macrophages during acute soft tissue infection. PLoS Med., 3 (3), e53.
159. Phelps, H.A., and Neely, M.N. (2007) SalY of the Streptococcus pyogenes lantibiotic locus is required for full virulence and intracellular survival in macrophages. Infect. Immun., 75 (9), 4541-4551.
160. Goldmann, O., et al. (2004) Role of macrophages in host resistance to group A streptococci. Infect. Immun., 72 (5), 2956-2963.
161. Gryllos, I., et al. (2008) PerR confers phagocytic killing resistance and allows pharyngeal colonization by group A streptococcus. PLoS Pathog, 4 (9), e1000145.
162. Goldmann, O., et al. (2007) Transcrip-tome analysis of murine macrophages in response to infection with Streptococcus pyogenes reveals an unusual activation program. Infect. Immun., 75 (8), 4148-4157.
163. Goshi, K., et al. (1961) Studies on the pathogenesis of staphylococcal infection. II. The effect of non-specific inflammation. J. Exp. Med., 249-257.113
164. Noble, W.C. (1965) The production of subcutaneous staphylococcal skin lesions in mice. Br. J. Exp. Pathol., 46 (3), 254-262.
165. Molne, L., and Tarkowski, A. (2000) An experimental model of cutaneous infection induced by superantigen-producing Staphylococcus aureus. J. Invest. Dermatol., 114 (6), 1120-1125.
166. Katakura, T., et al. (2005) Immunological control of methicillin-resistant Staphylococcus aureus (MRSA) infection in an immunodeficient murine model of thermal injuries. Clin. Exp. Immunol., 142 (3), 419-425.
167. Tanaka, H., et al. (2004) Role of macrophages in a mouse model of postoperative MRSA enteritis. J. Surg. Res., 118 (2), 114-121.
168. Kubica, M., et al. (2008) A potential new pathway for Staphylococcus aureus dissemination: the silent survival of S. aureus phagocytosed by human monocyte-derived macrophages. PLoS ONE, 3 (1), e1409.